SEC Filing Summary: Synta Pharmaceuticals Corp.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on December 1, 2011, reporting events occurring on November 30, 2011. The filing addresses a material definitive agreement regarding investor rights. Note: The request metadata referenced "Madrigal Pharmaceuticals," but the source text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment and does not contain financial performance data.
Material Changes
The primary material change reported is the execution of the Third Amendment to the Amended and Restated Investor Rights Agreement. Key details include:
- Parties: Synta Pharmaceuticals Corp. and certain stockholders, including directors Keith Gollust and Bruce Kovner.
- Context: The Company filed a shelf registration statement (Form S-3) in August 2011, requiring waivers of existing registration rights.
- Change: In consideration for these waivers, the termination date for registration rights was extended from February 9, 2012, to February 9, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are discussed beyond the standard incorporation by reference of the full amendment text (Exhibit 10.1).
Investor Verification Checklist
- Verify the full terms of the Third Amendment to the Investor Rights Agreement in Exhibit 10.1.
- Confirm the identity of the specific stockholders who waived registration rights in exchange for the extension.
- Review the status of the shelf registration statement (File No. 333-176022) to understand the capital raising context.
- Note the discrepancy between the request metadata (Madrigal Pharmaceuticals) and the actual filing registrant (Synta Pharmaceuticals).